share_log

Pfizer | 8-K: Pfizer's Financial Results for the Second Quarter of 2024

Pfizer | 8-K: Pfizer's Financial Results for the Second Quarter of 2024

辉瑞 | 8-K:2024年第二季度的财务业绩
美股SEC公告 ·  07/30 08:05
Moomoo AI 已提取核心信息
On July 30, 2024, Pfizer Inc. released its financial results for the second quarter of 2024. The announcement was made through a press release, which is now available as Exhibit 99. This information, while furnished to the Securities and Exchange Commission (SEC) in a Form 8-K filing, is not considered filed for Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any of Pfizer's other filings, unless explicitly stated. The press release provides detailed insights into Pfizer's operational and financial performance for the quarter.
On July 30, 2024, Pfizer Inc. released its financial results for the second quarter of 2024. The announcement was made through a press release, which is now available as Exhibit 99. This information, while furnished to the Securities and Exchange Commission (SEC) in a Form 8-K filing, is not considered filed for Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any of Pfizer's other filings, unless explicitly stated. The press release provides detailed insights into Pfizer's operational and financial performance for the quarter.
2024年7月30日,辉瑞公司公布了2024年第二季度的财务业绩。该公告发布在展品99中,展品已发布为新闻稿。尽管这些信息以8-k表格形式提交给了证券交易委员会(SEC),但不被视为根据《1934年证券交易法》第18条规定提交并不被纳入辉瑞的任何其他提交中,除非有明确说明。新闻稿提供了有关辉瑞第二季度运营和财务表现的详细信息。
2024年7月30日,辉瑞公司公布了2024年第二季度的财务业绩。该公告发布在展品99中,展品已发布为新闻稿。尽管这些信息以8-k表格形式提交给了证券交易委员会(SEC),但不被视为根据《1934年证券交易法》第18条规定提交并不被纳入辉瑞的任何其他提交中,除非有明确说明。新闻稿提供了有关辉瑞第二季度运营和财务表现的详细信息。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息